Insmed (INSM) to Release Earnings on Thursday

Insmed (NASDAQ:INSM) will likely be posting its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.6939) per share and revenue of $393.7440 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The company had revenue of $305.96 million during the quarter, compared to analysts’ expectations of $300.81 million. During the same quarter last year, the company posted ($1.42) EPS. The firm’s revenue was up 229.7% compared to the same quarter last year. On average, analysts expect Insmed to post $-2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Insmed Stock Up 0.3%

Insmed stock opened at $98.75 on Wednesday. Insmed has a twelve month low of $90.39 and a twelve month high of $212.75. The stock’s fifty day simple moving average is $104.32 and its 200-day simple moving average is $129.85. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. The firm has a market capitalization of $21.40 billion, a P/E ratio of -17.17 and a beta of 0.81.

Insiders Place Their Bets

In other Insmed news, COO Roger Adsett sold 2,370 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total transaction of $242,379.90. Following the sale, the chief operating officer owned 98,603 shares of the company’s stock, valued at approximately $10,084,128.81. This trade represents a 2.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO William Lewis sold 21,398 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $103.32, for a total transaction of $2,210,841.36. Following the sale, the chief executive officer owned 258,917 shares of the company’s stock, valued at $26,751,304.44. This represents a 7.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 54,590 shares of company stock worth $5,793,738. Insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of INSM. CIBC Private Wealth Group LLC lifted its position in Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 53 shares during the last quarter. Raiffeisen Bank International AG purchased a new position in shares of Insmed during the fourth quarter worth about $32,000. Towarzystwo Funduszy Inwestycyjnych PZU SA purchased a new position in shares of Insmed during the fourth quarter worth about $49,000. Summit Securities Group LLC acquired a new stake in shares of Insmed during the fourth quarter worth about $57,000. Finally, Transamerica Financial Advisors LLC increased its position in shares of Insmed by 72.3% during the fourth quarter. Transamerica Financial Advisors LLC now owns 348 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 146 shares in the last quarter.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Raymond James Financial assumed coverage on Insmed in a report on Friday, April 10th. They set an “outperform” rating and a $200.00 price target on the stock. BMO Capital Markets assumed coverage on Insmed in a research note on Monday, July 20th. They issued an “outperform” rating and a $192.00 price objective for the company. Truist Financial lowered their price objective on Insmed from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Cantor Fitzgerald restated an “overweight” rating and set a $235.00 target price on shares of Insmed in a research note on Tuesday, July 28th. Finally, Roth Capital reaffirmed a “buy” rating on shares of Insmed in a report on Monday, June 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Insmed has a consensus rating of “Buy” and an average price target of $209.35.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.